NCT06155955View on ClinicalTrials.gov

Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 22, 2023

Primary Completion Date

March 21, 2024

Study Completion Date

June 21, 2024

Conditions

Severe Hemophilia A Without InhibitorJoint Bleed

Interventions

DRUG

"Emicizumab, HEMLIBRA®"

low dose

Trial Locations (1)

10330

RECRUITING

King Chulalongkorn Memorial hospital, Bangkok

All Listed Sponsors

lead

Chulalongkorn University

OTHER